Cytodyn Inc (CYDY)

[kgromax]

Endpoint modified ex-post, which means it was a failure. And the 17 other secondary endpoints were failures. As well as the primary endpoint. Then, zero regulators, across all countries in the world, were interested in approving Leronlimab for mild/moderate patients based on that study. It's pretty obvious: CD10 was a huge failure